A new trading day began on Tuesday, with Cytek BioSciences Inc (NASDAQ: CTKB) stock price down -2.24% from the previous day of trading, before settling in for the closing price of $4.01. CTKB’s price has ranged from $3.90 to $7.63 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 29.59% over the past five years. Meanwhile, its annual earnings per share averaged -93.88%. With a float of $116.09 million, this company’s outstanding shares have now reached $129.21 million.
Let’s look at the performance matrix of the company that is accounted for 648 employees. In terms of profitability, gross margin is 62.9%, operating margin of -11.62%, and the pretax margin is -3.23%.
Cytek BioSciences Inc (CTKB) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Medical Devices Industry. The insider ownership of Cytek BioSciences Inc is 9.37%, while institutional ownership is 60.12%. The most recent insider transaction that took place on Apr 19 ’24, was worth 117,400. In this transaction CHIEF TECHNOLOGY OFFICER of this company sold 20,000 shares at a rate of $5.87, taking the stock ownership to the 5,988,502 shares. Before that another transaction happened on Apr 09 ’24, when Company’s CHIEF TECHNOLOGY OFFICER sold 1,900 for $7.00, making the entire transaction worth $13,304. This insider now owns 6,008,502 shares in total.
Cytek BioSciences Inc (CTKB) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -93.88% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -5.81% during the next five years compared to 18.28% growth over the previous five years of trading.
Cytek BioSciences Inc (NASDAQ: CTKB) Trading Performance Indicators
Here are Cytek BioSciences Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.21. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.51. Likewise, its price to free cash flow for the trailing twelve months is 22.98.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.04, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach 0.05 in one year’s time.
Technical Analysis of Cytek BioSciences Inc (CTKB)
Cytek BioSciences Inc (NASDAQ: CTKB) saw its 5-day average volume 0.77 million, a negative change from its year-to-date volume of 0.86 million. As of the previous 9 days, the stock’s Stochastic %D was 10.77%. Additionally, its Average True Range was 0.21.
During the past 100 days, Cytek BioSciences Inc’s (CTKB) raw stochastic average was set at 0.54%, which indicates a significant decrease from 3.60% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 35.03% in the past 14 days, which was lower than the 78.81% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.86, while its 200-day Moving Average is $5.60. Nevertheless, the first resistance level for the watch stands at $4.00 in the near term. At $4.09, the stock is likely to face the second major resistance level. The third major resistance level sits at $4.14. If the price goes on to break the first support level at $3.87, it is likely to go to the next support level at $3.82. Assuming the price breaks the second support level, the third support level stands at $3.73.
Cytek BioSciences Inc (NASDAQ: CTKB) Key Stats
With a market capitalization of 502.14 million, the company has a total of 128,097K Shares Outstanding. Currently, annual sales are 200,450 K while annual income is -6,020 K. The company’s previous quarter sales were 57,480 K while its latest quarter income was 9,640 K.
